Published • loading... • Updated
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial ...
The study will enroll 282 patients and uses overall survival as the primary endpoint after encouraging early results and manageable safety in Phase 1.
- On Friday, Shanghai Junshi Biosciences completed first patient dosing in a Phase 3 clinical trial of JS203, a bispecific antibody designed to treat relapsed or refractory DLBCL.
- DLBCL accounts for approximately 40% of adult NHL cases in China, with approximately 45,000 new cases annually characterized by high aggressiveness and rapid progression.
- JS203 demonstrated a 69.7% objective response rate in DLBCL patients during Phase 1 trials, with a manageable safety profile including a 27.3% cytokine release syndrome incidence.
- Led by Professor Yuqin SONG of Beijing Cancer Hospital, the randomized, open-label, multicenter study plans to enroll 282 subjects with overall survival as the primary endpoint.
- Headquartered in Shanghai, Junshi Biosciences employs more than 3,000 people globally and maintains an extensive portfolio including toripalimab, approved in over 50 countries and regions.
Insights by Ground AI
11 Articles
11 Articles
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial ...
SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing…
St Catharines Standard+8 Reposted by 8 other sources
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing…
·Welland, Canada
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left7Leaning Right2Center1Last UpdatedBias Distribution70% Left
Bias Distribution
- 70% of the sources lean Left
70% Left
L 70%
R 20%
Factuality
To view factuality data please Upgrade to Premium
